Financial Results : Almoosa posts SAR 102.9M in H1 2025, SAR 51.8 in Q2

Almoosa posts SAR 102.9M in H1 2025, SAR 51.8 in Q2

03/08/2025 Argaam Exclusive

View other reports

Almoosa Health Co. reported a net profit of SAR 102.9 million for H1 2025, compared to SAR 12.5 million in the year-earlier period.



Financials (M)

Item 6m 2024 6m 2025 Change‬
Revenues 561.75 671.95 19.6 %
Gross Income 153.71 210.88 37.2 %
Operating Income 51.54 102.20 98.3 %
Net Income 12.47 102.90 725.4 %
Average Shares 35.00 44.30 26.6 %
Earnings Per Share before unusual items (Riyals) 0.36 2.34 555.8 %
EPS (Riyal) 0.36 2.32 552.1 %

The profit growth was attributed to a 19.6% rise in revenues, reaching SAR 671.9 million in the six-month period.

 

This growth was mainly driven by strong performance across various operating segments, an increase in the number of inpatients, improved efficiency in the utilization of healthcare services, and lower financing costs (FCs) following the settlement of a loan earlier in the year.



Current Quarter Comparison (M)

Compared With The
Item Q2 2024 Q2 2025 Change‬
Revenues 284.59 348.97 22.6 %
Gross Income 75.17 112.09 49.1 %
Operating Income 20.90 54.14 159.0 %
Net Income (1.26) 51.77 4208.6 %
Average Shares 35.00 44.30 26.6 %
Earnings Per Share before unusual items (Riyal) (0.04) 1.21 3460.6 %
EPS (Riyal) (0.04) 1.17 3345.8 %

Net earnings for Q2 2025 soared to SAR 51.8 million, against a loss of SAR 1.26 million in Q2 2024.

 

On a sequential basis, net profit grew 1.3% from SAR 51.1 million in Q1 2025.

 

Total shareholders’ equity (no minority interest) rose to SAR 1.9 billion by June 30, 2025, compared to SAR 633.1 million in the prior-year period.

Attached document:

 

 

 

View More Financial Results

 


Financial results (Million)

Period Revenues Change Gross Income Change Operating Income Change
Q1 2016 - - - - - -
Q2 2016 - - - - - -
Q3 2016 - - - - - -
Q4 2016 - - - - - -
Q1 2017 - - - - - -
Q2 2017 - - - - - -
Q3 2017 - - - - - -
Q4 2017 - - - - - -
Q1 2018 - - - - - -
Q2 2018 - - - - - -
Q3 2018 - - - - - -
Q4 2018 - - - - - -
Q1 2019 - - - - - -
Q2 2019 - - - - - -
Q3 2019 - - - - - -
Q4 2019 - - - - - -
Q1 2020 - - - - - -
Q2 2020 - - - - - -
Q3 2020 - - - - - -
Q4 2020 - - - - - -
Q1 2021 - - - - - -
Q2 2021 - - - - - -
Q3 2021 - - - - - -
Q4 2021 - - - - - -
Q1 2022 - - - - - -
Q2 2022 - - - - - -
Q3 2022 - - - - - -
Q4 2022 - - - - - -
Q1 2023 232.66 - 69.80 - 27.69 -
Q2 2023 230.46 - 68.31 - 27.44 -
Q3 2023 243.04 - 65.85 - 30.96 -
Q4 2023 272.81 - 103.03 - 27.92 -
Q1 2024 277.16 19.1 % 78.54 12.5 % 30.64 10.7 %
Q2 2024 284.59 23.5 % 75.17 10.0 % 20.90 (23.8 %)
Q3 2024 308.48 26.9 % 98.07 48.9 % 47.42 53.2 %
Q4 2024 332.11 21.7 % 119.95 16.4 % 69.69 149.6 %
Q1 2025 322.98 16.5 % 98.79 25.8 % 48.06 56.8 %
Q2 2025 348.97 22.6 % 112.09 49.1 % 54.14 159.0 %


Profit Performance (Million)

Period Net Income Change EPS(Riyal) Extraordinary Income/Expense Net Profit Before Unusual Items EPS(Riyal)
Q1 2016 - - - - - -
Q2 2016 - - - - - -
Q3 2016 - - - - - -
Q4 2016 - - - - - -
Q1 2017 - - - - - -
Q2 2017 - - - - - -
Q3 2017 - - - - - -
Q4 2017 - - - - - -
Q1 2018 - - - - - -
Q2 2018 - - - - - -
Q3 2018 - - - - - -
Q4 2018 - - - - - -
Q1 2019 - - - - - -
Q2 2019 - - - - - -
Q3 2019 - - - - - -
Q4 2019 - - - - - -
Q1 2020 - - - - - -
Q2 2020 - - - - - -
Q3 2020 - - - - - -
Q4 2020 - - - - - -
Q1 2021 - - - - - -
Q2 2021 - - - - - -
Q3 2021 - - - - - -
Q4 2021 - - - - - -
Q1 2022 - - - - - -
Q2 2022 - - - - - -
Q3 2022 - - - - - -
Q4 2022 - - - - - -
Q1 2023 26.09 - 0.75 - 26.09 0.75
Q2 2023 22.30 - 0.64 - 22.30 0.64
Q3 2023 29.57 - 0.84 - 29.57 0.84
Q4 2023 20.18 - 0.58 - 20.18 0.58
Q1 2024 13.73 (47.4 %) 0.39 - 13.73 0.39
Q2 2024 (1.26) (105.7 %) (0.04) - (1.26) (0.04)
Q3 2024 27.93 (5.6 %) 0.80 - 27.93 0.80
Q4 2024 54.03 167.7 % 1.54 - 54.03 1.54
Q1 2025 51.13 272.5 % 1.15 1.24 49.89 1.13
Q2 2025 51.77 4208.6 % 1.17 (1.83) 53.60 1.21

Profitability

Period Gross Margin OIBDA Margin Net Margin Before Unusual Items
Q1 2016 - - -
Q2 2016 - - -
Q3 2016 - - -
Q4 2016 - - -
Q1 2017 - - -
Q2 2017 - - -
Q3 2017 - - -
Q4 2017 - - -
Q1 2018 - - -
Q2 2018 - - -
Q3 2018 - - -
Q4 2018 - - -
Q1 2019 - - -
Q2 2019 - - -
Q3 2019 - - -
Q4 2019 - - -
Q1 2020 - - -
Q2 2020 - - -
Q3 2020 - - -
Q4 2020 - - -
Q1 2021 - - -
Q2 2021 - - -
Q3 2021 - - -
Q4 2021 - - -
Q1 2022 - - -
Q2 2022 - - -
Q3 2022 - - -
Q4 2022 - - -
Q1 2023 - - -
Q2 2023 - - -
Q3 2023 - - -
Q4 2023 31.36 % - 10.03 %
Q1 2024 30.85 % - 8.38 %
Q2 2024 29.94 % - 5.77 %
Q3 2024 31.04 % 17.91 % 5.30 %
Q4 2024 30.92 % 20.96 % 7.85 %
2024 30.92 % 20.96 % 7.85 %
Q1 2025 31.40 % 21.77 % 10.46 %
Q2 2025 32.68 % 23.46 % 14.13 %


Per Share Data (Riyal)

Compared With The
Period Shares Outstanding (M) EPS (Riyal) Earnings Per Share before unusual items (Riyal) Book Value (BV)
Q1 2016 - - - -
Q2 2016 - - - -
Q3 2016 - - - -
Q4 2016 - - - -
Q1 2017 - - - -
Q2 2017 - - - -
Q3 2017 - - - -
Q4 2017 - - - -
Q1 2018 - - - -
Q2 2018 - - - -
Q3 2018 - - - -
Q4 2018 - - - -
Q1 2019 - - - -
Q2 2019 - - - -
Q3 2019 - - - -
Q4 2019 - - - -
Q1 2020 - - - -
Q2 2020 - - - -
Q3 2020 - - - -
Q4 2020 - - - -
Q1 2021 - - - -
Q2 2021 - - - -
Q3 2021 - - - -
Q4 2021 - - - -
Q1 2022 - - - -
Q2 2022 - - - -
Q3 2022 - - - -
Q4 2022 - - - -
Q1 2023 35.00 - - 19.26
Q2 2023 35.00 - - -
Q3 2023 35.00 - - 20.83
Q4 2023 35.00 2.80 2.80 18.74
Q1 2024 35.00 2.45 2.45 18.37
Q2 2024 35.00 1.78 1.78 18.09
Q3 2024 35.00 1.73 1.73 18.91
Q4 2024 35.00 2.70 2.70 20.51
Q1 2025 44.30 2.98 2.95 43.12
Q2 2025 44.30 4.17 4.19 43.08

Multiple Ratios (End of Period Price)

Compared With The
Period P/E Recurring P/E Price/book
Q1 2016 - - -
Q2 2016 - - -
Q3 2016 - - -
Q4 2016 - - -
Q1 2017 - - -
Q2 2017 - - -
Q3 2017 - - -
Q4 2017 - - -
Q1 2018 - - -
Q2 2018 - - -
Q3 2018 - - -
Q4 2018 - - -
Q1 2019 - - -
Q2 2019 - - -
Q3 2019 - - -
Q4 2019 - - -
Q1 2020 - - -
Q2 2020 - - -
Q3 2020 - - -
Q4 2020 - - -
Q1 2021 - - -
Q2 2021 - - -
Q3 2021 - - -
Q4 2021 - - -
Q1 2022 - - -
Q2 2022 - - -
Q3 2022 - - -
Q4 2022 - - -
Q1 2023 - - -
Q2 2023 - - -
Q3 2023 - - -
Q4 2023 - - -
Q1 2024 - - -
Q2 2024 - - -
Q3 2024 - - -
Q4 2024 - - -
Q1 2025 50.47 50.95 3.48
Q2 2025 38.87 38.75 3.77

Business Segments (Million)

Compared With The
Period medical services Pharmaceuticals Rehabilitation
Q1 2023 188.34 44.33 -
Q4 2023 200.95 56.36 15.50
Q1 2024 198.18 58.67 20.30
Q2 2024 172.08 70.77 41.74
Q4 2024 227.64 65.02 39.45
Q1 2025 214.15 74.30 34.53
Q2 2025 229.60 78.06 41.31

Analysts Estimates (Million)

Item Profit (Expected) Profit (Actual) Change Profit Before Unusual Items Change
Average 45.20 51.77 53.60

Estimates vs Actual (Million)

Item Profit (Expected) Profit (Actual) Change‬ Profit Before Unusual Items Change‬
AlJazira Capital 45.20 51.77 53.60


Financial Ratios
Current
Market Cap (M Riyal) 7,300.65
Enterprise Value (EV) (M Riyal) 7,737.86
Shares Outstanding ((M)) 44.30
EPS ( Riyal) (TTM) 4.17
Book Value (BV) ( Riyal) 43.08
Par Value ( Riyal) 10.00
Recurring P/E 39.37
P/E (TTM) 39.49
Price/book 3.83
Return on Average Assets (%) (TTM) -
Return on Average Equity (%) (TTM) 14.5
EV/adj EBITDA 25.12
EV/Revenues 5.90
more

Share Price

Almoosa Health Co.
164.80
(1.60) (0.96 %)

Almoosa Health Co. (ALMOOSA)

More

Comments {{getCommentCount()}}

Be the first to comment

{{Comments.indexOf(comment)+1}}
{{comment.FollowersCount}}
{{comment.CommenterComments}}

رد{{comment.DisplayName}} على {{getCommenterName(comment.ParentThreadID)}}

{{comment.DisplayName}} حساب موثّق

{{comment.ElapsedTime}}
loader Train
loader Train
Sorry: the validity period has ended to comment on this news
Opinions expressed in the comments section do not reflect the views of Argaam. Abusive comments of any kind will be removed. Political or religious commentary will not be tolerated.